LT2925338T - Liofilizuota tat-nr2b9c kompozicija - Google Patents
Liofilizuota tat-nr2b9c kompozicijaInfo
- Publication number
- LT2925338T LT2925338T LTEP13859059.1T LT13859059T LT2925338T LT 2925338 T LT2925338 T LT 2925338T LT 13859059 T LT13859059 T LT 13859059T LT 2925338 T LT2925338 T LT 2925338T
- Authority
- LT
- Lithuania
- Prior art keywords
- nr2b9c
- tat
- lyophilized formulation
- lyophilized
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261730952P | 2012-11-28 | 2012-11-28 | |
PCT/US2013/071755 WO2014085349A1 (en) | 2012-11-28 | 2013-11-25 | Lyophilized formulation of tat-nr2b9c |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2925338T true LT2925338T (lt) | 2019-05-10 |
Family
ID=50828392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP13859059.1T LT2925338T (lt) | 2012-11-28 | 2013-11-25 | Liofilizuota tat-nr2b9c kompozicija |
Country Status (19)
Country | Link |
---|---|
US (1) | US20140162957A1 (lt) |
EP (1) | EP2925338B8 (lt) |
JP (1) | JP6427104B2 (lt) |
KR (1) | KR102166374B1 (lt) |
CN (2) | CN105101986B (lt) |
AU (1) | AU2013352437B2 (lt) |
CA (1) | CA2892965C (lt) |
DK (1) | DK2925338T3 (lt) |
ES (1) | ES2725598T3 (lt) |
HK (1) | HK1215793A1 (lt) |
HR (1) | HRP20190707T1 (lt) |
HU (1) | HUE043820T2 (lt) |
LT (1) | LT2925338T (lt) |
MX (1) | MX365325B (lt) |
PL (1) | PL2925338T3 (lt) |
PT (1) | PT2925338T (lt) |
SI (1) | SI2925338T1 (lt) |
TR (1) | TR201905787T4 (lt) |
WO (1) | WO2014085349A1 (lt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
JP6707469B2 (ja) | 2014-05-28 | 2020-06-10 | ノノ インコーポレイテッド | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
WO2015181756A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Chloride salt of tat-nr2b9c |
EP3247400A1 (en) * | 2015-01-18 | 2017-11-29 | Biogen MA Inc. | Formulations and screening of biological therapeutic agents |
JP2019522675A (ja) * | 2016-04-27 | 2019-08-15 | ▲拝▼西欧斯(北京)生物技▲術▼有限公司 | 興奮製神経毒性に関連した損傷の治療方法 |
CN106619170A (zh) * | 2016-10-26 | 2017-05-10 | 暨南大学 | 包含stp和生长因子的活性组合物及其化妆品或护肤品 |
CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
US20080119412A1 (en) * | 2003-12-23 | 2008-05-22 | Nono Inc. | Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins |
GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
EP1910552A4 (en) * | 2005-06-23 | 2009-01-07 | Arbor Vita Corp | METHOD AND COMPOSITIONS FOR MODULATING COX |
US8633160B2 (en) * | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
US7981424B2 (en) * | 2006-05-05 | 2011-07-19 | Transtech Pharma, Inc. | RAGE fusion proteins, formulations, and methods of use thereof |
EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
WO2010028089A2 (en) * | 2008-09-03 | 2010-03-11 | Arbor Vita Corporation | Agents and methods for treatment of pain |
US8099602B2 (en) * | 2008-09-26 | 2012-01-17 | Mykonos Software, Inc. | Methods for integrating security in network communications and systems thereof |
EP2440230B1 (en) * | 2009-06-10 | 2020-11-11 | NoNO Inc. | Treatment regimes for treatment of neurological disease |
DK2440231T3 (da) * | 2009-06-10 | 2020-01-13 | Nono Inc | Co-administration af et middel bundet til et tat-internaliseringspeptid med en mastcelledegranuleringshæmmer |
CA2807946C (en) * | 2010-08-12 | 2018-09-25 | Nono Inc. | Treatment of penetrative injury to the brain |
-
2013
- 2013-11-25 MX MX2015006784A patent/MX365325B/es active IP Right Grant
- 2013-11-25 HU HUE13859059A patent/HUE043820T2/hu unknown
- 2013-11-25 WO PCT/US2013/071755 patent/WO2014085349A1/en active Application Filing
- 2013-11-25 TR TR2019/05787T patent/TR201905787T4/tr unknown
- 2013-11-25 PL PL13859059T patent/PL2925338T3/pl unknown
- 2013-11-25 LT LTEP13859059.1T patent/LT2925338T/lt unknown
- 2013-11-25 JP JP2015545156A patent/JP6427104B2/ja active Active
- 2013-11-25 CA CA2892965A patent/CA2892965C/en active Active
- 2013-11-25 AU AU2013352437A patent/AU2013352437B2/en not_active Ceased
- 2013-11-25 PT PT13859059T patent/PT2925338T/pt unknown
- 2013-11-25 CN CN201380071653.2A patent/CN105101986B/zh active Active
- 2013-11-25 DK DK13859059.1T patent/DK2925338T3/da active
- 2013-11-25 KR KR1020157017140A patent/KR102166374B1/ko active IP Right Grant
- 2013-11-25 SI SI201331425T patent/SI2925338T1/sl unknown
- 2013-11-25 EP EP13859059.1A patent/EP2925338B8/en active Active
- 2013-11-25 CN CN201810971184.4A patent/CN109106941A/zh active Pending
- 2013-11-25 ES ES13859059T patent/ES2725598T3/es active Active
- 2013-11-26 US US14/089,752 patent/US20140162957A1/en not_active Abandoned
-
2016
- 2016-04-01 HK HK16103755.1A patent/HK1215793A1/zh unknown
-
2019
- 2019-04-16 HR HRP20190707TT patent/HRP20190707T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
KR102166374B1 (ko) | 2020-10-15 |
WO2014085349A1 (en) | 2014-06-05 |
TR201905787T4 (tr) | 2019-05-21 |
HK1215793A1 (zh) | 2016-09-15 |
US20140162957A1 (en) | 2014-06-12 |
MX2015006784A (es) | 2015-10-29 |
EP2925338A1 (en) | 2015-10-07 |
CN105101986B (zh) | 2018-09-25 |
CA2892965C (en) | 2021-06-01 |
JP6427104B2 (ja) | 2018-11-21 |
EP2925338A4 (en) | 2016-05-25 |
AU2013352437A1 (en) | 2015-07-09 |
JP2016502537A (ja) | 2016-01-28 |
CN105101986A (zh) | 2015-11-25 |
SI2925338T1 (sl) | 2019-09-30 |
DK2925338T3 (da) | 2019-05-06 |
HUE043820T2 (hu) | 2019-09-30 |
KR20150094656A (ko) | 2015-08-19 |
BR112015012422A2 (pt) | 2017-09-12 |
EP2925338B1 (en) | 2019-03-27 |
MX365325B (es) | 2019-05-29 |
EP2925338B8 (en) | 2019-05-22 |
CA2892965A1 (en) | 2014-06-05 |
PT2925338T (pt) | 2019-05-31 |
CN109106941A (zh) | 2019-01-01 |
PL2925338T3 (pl) | 2019-11-29 |
AU2013352437B2 (en) | 2018-04-12 |
HRP20190707T1 (hr) | 2019-10-04 |
ES2725598T3 (es) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212701A1 (zh) | 恩雜魯胺製劑 | |
HRP20190841T1 (hr) | Injektabilna formulacija | |
HK1215793A1 (zh) | 的凍乾製劑 | |
EP2917314A4 (en) | OLIGOMERATZUSAMMENSETZUNG | |
PL2833884T3 (pl) | Zastosowanie inhibitorów ccr3 | |
HK1202445A1 (en) | New formulation | |
HK1191245A1 (zh) | 阿立哌唑的凍乾製劑 | |
IL236312A0 (en) | Preparation of 18f-flucyclobin | |
EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
EP3560952C0 (en) | VARIANT OF BPIFB4 PROTEIN | |
EP2822599A4 (en) | VACCINE | |
GB201211247D0 (en) | Improved formulation | |
GB201217666D0 (en) | Construction of surfaces |